Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - a / vietnamo / 1194/2004 (h5n1) viruso gripo viruso paviršiaus antigenai (hemagliutininas ir neuraminidazė) - influenza, human; immunization; disease outbreaks - vakcinos - imunizacijai nuo h5n1 potipio gripo virusas. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Zoonotic Influenza Vaccine Seqirus Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

zoonotic influenza vaccine seqirus

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vakcinos - active immunisation against h5 subtype of influenza a virus.

Porcilis ColiClos Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

porcilis coliclos

intervet international bv - clostridium perfringens c tipo / escherichia coli f4ab / e. coli f4ac / e. coli f5 / e. coli f6 / e. coli lt - imunologiniai preparatai - kiaulės - dėl pasyvios imunizacijos palikuonių, kuriuos aktyvios imunizacijos nuo paršavedės ir kiaulaitės sumažinti mirtingumą ir klinikinių požymių per pirmąsias gyvenimo dienas, kurias sukelia tokios escherichia coli štamų, kurie išreikšti adhesins f4ab (k88ab), f4ac (k88ac), f5 (k99) arba f6 (987p) ir sukelia clostridium perfringens c tipo.

Netvax Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

netvax

intervet international bv - clostridium-perfringens tipo a alfa toksoidas - imunologiniai vaistai - vištiena - veiklioji viščiukų imunizacija, siekiant paskiepyti pasyvią imunizaciją nuo nekrotinio enterito savo palikuonims. norint sumažinti clostridium-perfringens tipo a-sukelto nekrotinio enterito mirtingumą ir paplitimą bei sunkumą. veiksmingumas buvo įrodytas išbandant viščiukus maždaug tris savaites po perinti. pradžia pasyvus perduoti imunitetą: 6 savaites po skiepijimo procedūra. pasyviojo imuniteto perdavimo trukmė: 51 savaitė po skiepijimo procedūros pabaigos.

Enteroporc Coli AC Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

enteroporc coli ac

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - kiaulės - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Suiseng Diff/A Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

suiseng diff/a

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - kiaulės - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

COVID-19 Vaccine (inactivated, adjuvanted) Valneva Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

covid-19 vaccine (inactivated, adjuvanted) valneva

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vakcinos - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Spikevax (previously COVID-19 Vaccine Moderna) Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcinos - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

ProteqFlu-Te Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

proteqflu-te

boehringer ingelheim vetmedica gmbh - clostridium tetani toxoid / virtualusis bendras fondas 2242 virusas / vcp1529 virusas / vcp1533 virusas / vcp3011 virusas - immunologicals for equidae, live viral and inactivated bacterial vaccines, equine influenza virus + clostridium - arkliai - aktyvios imunizacijos arklių keturių mėnesių amžiaus arba vyresnis nuo arklių gripo sumažinti klinikinius ligos požymius ir virusų išskyrimą po infekcijos, ir nuo stabligės, siekiant užkirsti kelią mirtingumas.

PreHevbri Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

prehevbri

vbi vaccines b.v. - hepatito b paviršinis antigenas - hepatitas b - vakcinos - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.